Altres autors/es

Institut Català de la Salut

[Mujanovic A] University Institute of Diagnostic and Interventional Neuroradiology, University Hospital Bern Inselspital, University of Bern, Bern, Switzerland. Department of Neurology, University Hospital Bern Inselspital, University of Bern, Bern, Switzerland. [Kurmann CC, Dobrocky T] University Institute of Diagnostic and Interventional Neuroradiology, University Hospital Bern Inselspital, University of Bern, Bern, Switzerland. [Olivé-Gadea M] Servei de Neurologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Maegerlein C] Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. [Pierot L] Department of Neuroradiology, University Hospital Reims, Reims, France

Vall d'Hebron Barcelona Hospital Campus

Data de publicació

2023-01-13T13:10:15Z

2023-01-13T13:10:15Z

2022-08-03



Resum

Atrial fibrillation; Intravenous thrombolysis; Oral anticoagulation


Fibrilación auricular; Trombólisis intravenosa; Anticoagulación oral


Fibril·lació auricular; Trombolisi intravenosa; Anticoagulació oral


Background and purpose: 40% of acute ischemic stroke patients treated by mechanical thrombectomy (MT) have a clinical history of atrial fibrillation (AF). The safety of bridging intravenous thrombolysis (IVT) (MT + IVT) is currently being discussed. We aimed to analyze the interaction between oral anticoagulation (OAC) status or AF with bridging IVT, regarding the occurrence of symptomatic intracranial hemorrhage (sICH) and functional outcome. Materials and Methods: Multicentric observational cohort study (BEYOND-SWIFT registry) of consecutive patients undergoing MT between 2010 and 2018 (n = 2,941). Multinomial regression models were adjusted for prespecified baseline and plausible pathophysiological covariates identified on a univariate analysis to assess the association of AF and OAC status with sICH and good outcomes (90-day modified Rankin Scale score 0–2). Results: In the total cohort (median age 74, 50.6% women), 1,347 (45.8%) patients had AF. Higher admission National Institutes of Health Stroke Scale (NIHSS) score (aOR 1.04 [95% 1.02–1.06], per point of increase) and prior medication with Vitamin K antagonists (VKA) (aOR 2.19 [95% 1.27–3.66]) were associated with sICH. Neither AF itself (aOR 0.71 [95% 0.41–1.24]) nor bridging IVT (aOR 1.08 [0.67–1.75]) were significantly associated with increased sICH. Receiving bridging IVT (aOR 1.61 [95% 1.24–2.11]) was associated with good 90-day outcome, with no interaction between AF and IVT (p = 0.92). Conclusion: Bridging IVT appears to be a reasonable clinical option in selected patients with AF. Given the increased sICH risk in patients with VKA, subgroup analysis of the randomized controlled trials should analyze whether patients with VKA might benefit from withholding bridging IVT.


This study was funded by the Bangerter-Rhyner Foundation and the Swiss Academy of Medical Sciences. Open access funding provided by University of Bern.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

Frontiers Media

Documents relacionats

Frontiers in Neurology;13

https://doi.org/10.3389/fneur.2022.945338

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)